Awridian is an established consultancy at the forefront early phase pharmaceutical research, specifically hit and lead generation and optimisation, with experience in High Throughput Screening, Affinity Selection Mass Spectrometry, DEL, and Fragment screening.

Furthermore, Awridian recognises that designing and acquiring the appropriate compounds for lead identification, or for larger projects such as refreshing screening collections is critical.  In addition, Awridian can advise on the tractability of Medicinal Chemistry Projects and how to enhance your chance of success.

Areas of expertise are illustrated by patents, publications and presentations which include topics such as new modalities, open innovation, a wide range of therapeutic areas, along with the design and acquisition of building blocks and screening collections.